On November 14, 2024, BeiGene USA, Inc. and BeiGene Switzerland GmbH reached a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd., resolving patent litigation related to BRUKINSA (zanubrutinib). The litigation was initiated in response to MSN's ANDA filing seeking approval for a generic version of BRUKINSA. BeiGene granted MSN the right to sell a generic version in the US no earlier than June 15, 2037, subject to potential adjustments.The composition of matter patent for BRUKINSA, expiring in April 2034, was not challenged in the litigation. This settlement, along with the previous dismissal of litigation against Sandoz Inc., resolves all patent litigation brought by BeiGene against companies seeking to market generic versions of BRUKINSA. As required by law, the settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice.

On November 14, 2024, BeiGene USA, Inc. and BeiGene Switzerland GmbH reached a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd., resolving patent litigation related to BRUKINSA (zanubrutinib). The litigation was initiated in response to MSN's ANDA filing seeking approval for a generic version of BRUKINSA. BeiGene granted MSN the right to sell a generic version in the US no earlier than June 15, 2037, subject to potential adjustments.The composition of matter patent for BRUKINSA, expiring in April 2034, was not challenged in the litigation. This settlement, along with the previous dismissal of litigation against Sandoz Inc., resolves all patent litigation brought by BeiGene against companies seeking to market generic versions of BRUKINSA. As required by law, the settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice.